Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for IXEKIZUMAB
- Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
- A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
- Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
- COVID-19 VaccinE Response in Rheumatology Patients
- Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
- Targeting IL-17A for Treatment-Resistant Depression
- Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Ixekizumab Diabetes Intervention Trial (I-DIT)
- Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
- A Study of Two Formulations of Ixekizumab in Healthy Participants
- A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
- A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
- A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
- Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
- Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
- A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
- Ixekizumab in the Treatment of Bullous Pemphigoid
- A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
- Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
- A Study of Ixekizumab in Participants With Plaque Psoriasis
- A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
- A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
- A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
- A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
- A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
- A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
- A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
- Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
- Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
- A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
- A Study in Japanese Participants With Moderate-to-Severe Psoriasis
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
- A Study in Participants With Moderate to Severe Psoriasis
- A Study in Patients With Rheumatoid Arthritis
Clinical trials list
click for details